{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029522","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.965119+00:00","generated_at":"2026-06-11T06:20:05.245933+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos receives Nasdaq deficiency notice for stockholders' equity below $2.5M","bullets":["Stockholders' equity as of June 30, 2023 was approx. $2.106M, below Nasdaq's $2.5M minimum.","Company has until October 2, 2023 to submit a compliance plan to Nasdaq.","If plan accepted, Nasdaq may grant extension through February 13, 2024.","Failure to regain compliance could lead to delisting; no immediate impact on listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029522","json":"https://secwatch.observer/filing/0001493152-23-029522.json","markdown":"https://secwatch.observer/filing/0001493152-23-029522.md","text":"https://secwatch.observer/filing/0001493152-23-029522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/0001493152-23-029522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:20:05.245933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"742eec5ac994e51ce2fb3619c21b277b5d5c236c","claim":"Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2023 was approximately $2,106,000. The Staff’s notice has no immediate impact on the listing of the Company’s common stock on Nasdaq. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days,","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/0001493152-23-029522-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}